205 related articles for article (PubMed ID: 23183429)
61. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
Avivi I; Cohen YC; Joffe E; Benyamini N; Held-Kuznetsov V; Trestman S; Terpos E; Dimopoulos MA; Kastritis E
Hematol Oncol; 2017 Dec; 35(4):734-740. PubMed ID: 27641057
[TBL] [Abstract][Full Text] [Related]
62. Atypical imaging feature of non-secretory multiple myeloma.
Neeravari A; Netravati P; Mohammed R; Ragupathi AR; Nagarajappa AH
Ann Diagn Pathol; 2011 Aug; 15(4):268-72. PubMed ID: 21546295
[TBL] [Abstract][Full Text] [Related]
63. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
[TBL] [Abstract][Full Text] [Related]
64. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.
Shah R; Stieltjes B; Andrulis M; Pfeiffer R; Sumkauskaite M; Delorme S; Schlemmer HP; Goldschmidt H; Landgren O; Hillengass J
Ann Hematol; 2013 Nov; 92(11):1553-7. PubMed ID: 23680869
[TBL] [Abstract][Full Text] [Related]
65. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
[TBL] [Abstract][Full Text] [Related]
66. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma.
Pika T; Minarik J; Schneiderka P; Budikova M; Langova K; Lochman P; Bacovsky J; Farbiakova V; Scudla V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun; 152(1):61-4. PubMed ID: 18795076
[TBL] [Abstract][Full Text] [Related]
67. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.
Suehara Y; Takamatsu H; Fukumoto K; Fujisawa M; Narita K; Usui Y; Takeuchi M; Endean K; Matsue K
Cancer Sci; 2017 Feb; 108(2):187-192. PubMed ID: 27889936
[TBL] [Abstract][Full Text] [Related]
68. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
[TBL] [Abstract][Full Text] [Related]
69. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.
Migkou M; Avivi I; Gavriatopoulou M; Cohen YC; Fotiou D; Kanellias N; Ziogas D; Eleutherakis-Papaiakovou E; Terpos E; Roussou M; Kastritis E; Dimopoulos MA
Ann Hematol; 2020 Jun; 99(6):1251-1255. PubMed ID: 32307566
[TBL] [Abstract][Full Text] [Related]
70. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
[TBL] [Abstract][Full Text] [Related]
71. Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma.
Patel UH; Drabick JJ; Malysz J; Talamo G
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e515-e519. PubMed ID: 30201257
[TBL] [Abstract][Full Text] [Related]
72. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
Kastritis E; Zagouri F; Symeonidis A; Roussou M; Sioni A; Pouli A; Delimpasi S; Katodritou E; Michalis E; Michael M; Hatzimichael E; Vassou A; Repousis P; Christophoridou A; Kartasis Z; Stefanoudaki E; Megalakaki C; Giannouli S; Kyrtsonis MC; Konstantopoulos K; Spyroupoulou-Vlachou M; Terpos E; Dimopoulos MA;
Leukemia; 2014 Oct; 28(10):2075-9. PubMed ID: 24637336
[TBL] [Abstract][Full Text] [Related]
73. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.
Binder M; Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Lust JA; Kapoor P; Lin Y; Go RS; Hwa YL; Kyle RA; Kumar SK
Am J Hematol; 2015 Oct; 90(10):888-91. PubMed ID: 26148022
[TBL] [Abstract][Full Text] [Related]
74. Smoldering multiple myeloma: when to observe and when to treat?
Mateos MV; San Miguel JF
Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213
[TBL] [Abstract][Full Text] [Related]
75. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
76. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
[No Abstract] [Full Text] [Related]
77. Advances in the management of asymptomatic myeloma.
Mateos MV
Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of the heavy/light-chain assay for the diagnosis and monitoring of multiple myeloma.
Chae H; Cha K; Kim M; Kim Y; Min CK
Int J Lab Hematol; 2013 Oct; 35(5):e10-2. PubMed ID: 23311353
[No Abstract] [Full Text] [Related]
79. New approaches to smoldering myeloma.
Mateos MV; San Miguel JF
Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
[TBL] [Abstract][Full Text] [Related]
80. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
